All In Biotech

Drug Trial Radar · NCT03205995

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents

Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

6

Actual

Start

May 2, 2018

Primary completion

Feb 2, 2021

Study completion Feb 2, 2021

Sponsor

Lead sponsor
Omeros CorporationIndustry
Sponsor type
Industry
First posted
Jul 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 (narsoplimab) in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).

Conditions

  • Thrombotic Microangiopathies
  • Atypical Hemolytic Uremic Syndrome

Interventions

  • OMS721 (narsoplimab)Biological

    Intravenous loading dose followed by daily subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26Time frame: Week 26

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Omeros Investigational Site

    Chicago, Illinois

  • Omeros Investigational Site

    Vilnius, Lithuania

  • Omeros Investigational Site

    Lodz, Poland

  • Omeros Investigational Site

    New Taipei City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.